Feasibility defined as the ability of tandutinib to achieve a target tumor/plasma ratio >= 0.33 (Phase I) Up to 4 years [clinicaltrials_resource:8f8922a8d135286eac881af52d7c3cd1]

Feasibility defined as the ability of tandutinib to achieve a target tumor/plasma ratio >= 0.33 (Phase I) Up to 4 years [clinicaltrials_resource:8f8922a8d135286eac881af52d7c3cd1]

Will be estimated along with 95% confidence intervals.
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:8f8922a8d135286eac881af52d7c3cd1
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma [clinicaltrials:NCT00379080]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Feasibility defined as the ability of tandutinib to achieve a target tumor/plasma ratio >= 0.33 (Phase I) Up to 4 years [clinicaltrials_resource:8f8922a8d135286eac881af52d7c3cd1]

Will be estimated along with 95% confidence intervals.
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:8f8922a8d135286eac881af52d7c3cd1
Bio2RDF identifier
8f8922a8d135286eac881af52d7c3cd1
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:8f8922a8d135286eac881af52d7c3cd1
measure [clinicaltrials_vocabulary:measure]
Feasibility defined as the abi ...... plasma ratio >= 0.33 (Phase I)
time frame [clinicaltrials_vocabulary:time-frame]
description
Will be estimated along with 95% confidence intervals.
identifier
clinicaltrials_resource:8f8922a8d135286eac881af52d7c3cd1
title
Feasibility defined as the abi ...... = 0.33 (Phase I) Up to 4 years
@en
inDataset
type
label
Feasibility defined as the abi ...... 922a8d135286eac881af52d7c3cd1]
@en